Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|October 26, 2026

The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis

Merck and Kelun’s sac-TMT extends overall survival in pretreated endometrial cancer, Bristol Myers Squibb reports interim data and a patient death in its phase 1 CAR-T trial in multiple sclerosis, and BioNTech and DualityBio’s HER2 ADC meets its phase 3 goal but with limited expected benefit.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. We’re looking at a survival benefit in hard-to-treat endometrial cancer, early data and a patient death in a CAR-T trial for multiple sclerosis, and a breast cancer win that its developers say may not change practice.

First, Merck and Kelun-Biotech’s sacituzumab tirumotecan, or sac-TMT, has extended survival by nearly 7 months in patients with advanced or recurrent endometrial cancer. Sac-TMT is an antibody-drug conjugate that targets TROP2, a protein found on many tumor cells. The phase 3 TroFuse-005 trial enrolled 776 patients whose cancer had progressed after both platinum chemotherapy and immunotherapy. Median overall survival was 19 months with sac-TMT, compared with 12.1 months with chemotherapy. Severe treatment-related side effects were more common with sac-TMT, most often anemia and low white blood cell counts. The FDA has accepted the application for priority review, with a decision expected by June 15, 2027.

Next, Bristol Myers Squibb has reported interim data and a patient death from its phase 1 Breakfree-2 trial of zola-cel, a CD19-targeted CAR-T therapy, in people with multiple sclerosis. In the 66-patient study, all 60 patients at the higher dose level were off their standard MS therapies at last follow-up. Among evaluable patients with progressive MS, 92% had stable or improved disability. However, one patient with relapsing MS developed late-onset motor symptoms, later received high-dose cyclophosphamide, and died of septic pneumonia 44 days after infusion. BMS said no other treatment-related deaths have occurred across 190 patients in its zola-cel autoimmune studies.

And BioNTech and DualityBio’s HER2-targeted antibody-drug conjugate has met its phase 3 goal, but the companies say the benefit may be limited. In the DYNASTY-Breast02 trial, trastuzumab pamirtecan improved progression-free survival over chemotherapy in 541 patients with HR-positive, HER2-low metastatic breast cancer. The improvement was described as modest, and the companies did not disclose the figures. Rates of interstitial lung disease, a known risk with this class of drugs, were higher than in earlier studies. A similar drug, AstraZeneca and Daiichi Sankyo’s Enhertu, is already approved in this setting. The companies say they will discuss the data before deciding on next steps.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Endometrial cancer: Sac-TMT extended median overall survival to 19 months vs 12.1 months with chemotherapy in the phase 3 TroFuse-005 trial.
  • CAR-T in MS: Early zola-cel data showed patients off standard therapies, but one patient died of septic pneumonia after treatment.
  • Limited benefit: Trastuzumab pamirtecan met its phase 3 PFS goal, but an approved competitor narrows its potential role in HER2-low breast cancer.

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.